Atreca, Inc. (BCEL) is one of the leading biotherapeutic company which is primarily focused on making therapeutics related to the antibodies which are used to cure solid tumors. Some of the lead candidates of the company include ATRC-101 can react with ovarian, colorectal, and breast cancer samples. The company is also engaged in the development of CD3 bispecific antibodies.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The price of BCEL stock during the regular trading on January 4, 2022, was $2.88 with a slight decline of 1.71%. At last check in the aftermarket, the stock was up by 5.56%.
BCEL: Events and Happenings
On January 04, 2022, BCEL reported about the representation of its data related to COVID-19 antibodies which can be broadly neutralized, at the Keystone Symposia Virtual Conference: Antibodies as Drugs, which will be held from January 30-February 2, 2022.
BCEL: CSO Comments
Speaking at the occasion, the chief strategy officer of BCEL, Tito A. Serafini, said that the company believes that its antibodies with promising and elaborated profiles are supportive in treating COVID-19. He further added that the data showed the capability of the company’s products to target emerging variants.
On November 08, 2021, BCEL reported that the company’s Executives presented the company at three virtual investor conferences. They include Cowen’s 5th Annual IO Next Summit on November 15, Stifel Nicolaus Healthcare Conference 1 on November 15, 2021, and Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021.
BCEL: Key Financials
On November 02, 2021, BCEL reported its financial results for the third quarter ended September 30, 2021. Some of the main updates are as follows
Net Loss per Share
Basic and diluted net loss for third-quarter 2021 was $27.4 million, or $0.74 per share as compared to the same period of 2020 when it was $22.9 million or $0.66 per share.
Total Current Assets
Total current assets of the company for Q3 2021 were $162 million as compared to $264 million for the same period of 2020.
On October 21, 2021, BCEL reported about its entry into a licensing contract with the Bill & Melinda Gates Medical Research Institute for the development of MAM01/ATRC-501. ATRC-501 is an innovative monoclonal antibody in preclinical trials for the treatment of malaria. On October 01, 2021, BCEL reported about two poster presentations at the SITC 2021 Annual Meeting, held on November 10-14, 2021.
BCEL’s stock is 67% low as compared to six months period. Although the stock significantly inclined in the aftermarket, yet the analysts are hopeful about the influx of investments in the company. The company’s stock possibly increased due to its announcement about the presentation of its research data on a bigger platform.